END-VT
Prospective cohort for the secondary prevention of Ventricular Tachycardia inpatients with cardiomyopathies (END-VT)
To determine the incidence of VAs and all-cause mortality among patients
with cardiomyopathy-induced VA.
Lead PI & Sponsor
Dr. Lorne Gula
Local PI
Dr. Lorne Gula
Research Staff
Sara El-Richani
Objective
Catheter ablation will, in comparison to antiarrhythmic drug therapy reduce the composite outcome of death at any time, appropriate ICD shock after 14 days, ventricular tachycardia storm after 14 days or treated sustained ventricular tachycardia below the detection rate of the ICD for patients with prior myocardial infarction and sustained monomorphic ventricular tachycardia.
Target Number of Patients
500
Currently Enrolled
9
Primary Outcomes
- The primary outcome is the composite of: All-cause mortality, appropriate ICD shock, VT storm, incessant VT, and sustained VT below detection rate of the ICD.
Secondary Outcomes
- Cardiovascular mortality
- Sudden cardiac death (SCD)
- Appropriate ATP
- New/worsening HF (defined as admission for HF and/or increase in dose of diuretic medication)
- Heart transplant
- Inappropriate shock or ATP
Inclusion Criteria
- First (new) diagnosis of sustained VA (monomorphic VT, polymorphic VT, or VF) documented (by an ECG, cardiac monitor, AED, and/or intracardiac pacemaker/ICD electrograms) within ≤90 days prior to enrolment
- Presence of previously implanted ICD, or plan for ICD implant during index hospitalization
- Diagnosis of cardiomyopathy (ie. ICM, hypertrophic, dilated, arrhythmogenic cardiomyopathy, or other myocardial scar)
- ICD clinical follow-up planned
Exclusion Criteria
- Patients with a ventricular arrhythmia which is thought to be due to a reversible cause.
To determine the incidence of VAs and all-cause mortality among patients
with cardiomyopathy-induced VA.